書誌情報

P6-6. Teclistamab in combination with daratumumab and lenalidomide in patients with multiple myeloma (Majes TEC-2) (Encore)

Emma Searle1, Hang Quach2, Sandy W. Wong3, Luciano Costa4, Cyrille Hulin5, Wojciech Janowski6, Jesus Berdeja7, Sebastien Anguille8, Jeffrey Matous9, Cyrille Touzeau10, Anne-Sophie Michallet11, Marla Husnik12, Deeksha Vishwamitra12, Zhuolu Niu13, Julie Larsen14, Lingling Chen15, Jenna D. Goldberg16, Rakesh Popat17, Andrew Spencer18
1The Christie Hospital, University of Manchester, 2University of Melbourne, St. Vincent's Hospital, 3UCSF Helen Diller Family Comprehensive Cancer Center, 4University of Alabama at Birmingham, 5Hopital Haut Leveque, University Hospital, 6Calvary Mater Newcastle, 7Sarah Cannon Research Institute, 8Antwerp University Hospital, 9Colorado Blood Cancer Institute, 10University Hospital Hotel-Dieu, 11Centre Hospitalier Lyon Sud, Hospices Civils, 12Janssen Research & Development, San Diego, 13Janssen Research & Development, Shanghai, 14Janssen Research & Development, Los Angeles, 15Janssen Research & Development, Spring House, 16Janssen Research & Development, Raritan, 17University College London Hospitals, NHS Foundation Trust, 18Monash University
International Journal of Myeloma 13(3): 167-167, 2023.

個人会員・法人会員の方(IDが5または10で始まる方)

  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。

ライブラリー会員の方(IDが11または12で始まる方)